Pulmonx Corporation (LUNG)
NASDAQ: LUNG
· Real-Time Price · USD
3.77
-1.06 (-21.95%)
At close: May 01, 2025, 3:59 PM
3.77
0.13%
After-hours: May 01, 2025, 04:05 PM EDT
-21.95% (1D)
| Bid | 3.73 |
| Market Cap | 151.53M |
| Revenue (ttm) | 83.79M |
| Net Income (ttm) | -56.39M |
| EPS (ttm) | -1.44 |
| PE Ratio (ttm) | -2.61 |
| Forward PE | -3.43 |
| Analyst | Buy |
| Ask | 3.79 |
| Volume | 1,464,741 |
| Avg. Volume (20D) | 365,816 |
| Open | 5.34 |
| Previous Close | 4.83 |
| Day's Range | 3.60 - 5.46 |
| 52-Week Range | 3.60 - 10.01 |
| Beta | 0.61 |
About LUNG
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence...
Industry Medical - Devices
Sector Healthcare
IPO Date Oct 1, 2020
Employees 291
Stock Exchange NASDAQ
Ticker Symbol LUNG
Website https://pulmonx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for LUNG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 218.73% from the latest price.
Stock ForecastsEarnings Surprise
Pulmonx has released their quartely earnings
on Apr 30, 2025:
2 hours ago
Pulmonx shares are trading lower after the company...
Unlock content with
Pro Subscription
2 months ago
+32.23%
Pulmonx shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 sales guidance above estimates.
